Status:
ACTIVE_NOT_RECRUITING
Detection of Early Idiopathic Pulmonary Fibrosis
Lead Sponsor:
Temple University
Collaborating Sponsors:
Boehringer Ingelheim
Conditions:
Idiopathic Pulmonary Fibrosis
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of the study is to determine if miR200 family may serve as a biomarker of IPF.
Eligibility Criteria
Inclusion
- Inclusion Criteria for IPF Patients:
- Informed consent
- Subjects ≥ 40 y.o.
- Naive patients with no IPF treatment
- IPF diagnosis based on the ATS/ERS/JRS/ALAT criteria
- Inclusion Criteria for non-IPF ILD Patients:
- Informed consent
- Subjects ≥ 18 y.o.
- ILD diagnosis
- Exclusion Criteria:
- HIV
- Hepatitis B
- Hepatitis C
- Pregnant or lactating women
- inclusion criteria for controls: informed consent \>18 years old; no lung diseases
Exclusion
Key Trial Info
Start Date :
April 10 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 30 2026
Estimated Enrollment :
450 Patients enrolled
Trial Details
Trial ID
NCT03457935
Start Date
April 10 2018
End Date
August 30 2026
Last Update
December 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Temple University
Philadelphia, Pennsylvania, United States, 19140